Yayınlar & Eserler

Yayın Ağı
Makaleler 28
Tümü (28)
SCI-E, SSCI, AHCI (25)
SCI-E, SSCI, AHCI, ESCI (26)
Scopus (28)
TRDizin (4)

1. Comparison of 6 cycles with 4 cycles of chemotherapy and atezolizumab in the first-line treatment of ES-SCLC: a retrospective multicenter analysis

Güzel H. G., KIVRAK SALİM D., Kılıçkap S., Kemal Y., Akosman C., Köseoğlu Ç., et al.
Oncologist , cilt.31, sa.4, 2026 (SCI-Expanded, Scopus)

2. Efficacy and safety of second-line treatments in ALK mutation-positive advanced non-small cell lung cancer after second- or third-generation ALK inhibitors: Turkish Oncology Group real-life study (TOG study)

Erol C., Zeynelgil E., Hizal M., Dumludag A., Erciyestepe M., Kalaci E., et al.
Clinical and Translational Oncology , 2026 (SCI-Expanded, Scopus)

3. Treatment Outcomes and Prognostic Factors Affecting Survival in Thymic Carcinoma

Koçanoğlu A., Düzköprü Y., Zeynelgil E., GÜRÇAY N., KARAKAYA S., Yazılıtaş D.
Acta Haematologica Oncologica Turcica , cilt.58, sa.3, ss.240-244, 2025 (Scopus, TRDizin) Creative Commons License

4. Real-World Outcomes in BRAF-Mutant Non-small Cell Lung Cancer: A Multicenter Analysis From the Turkish Oncology Group

Telli T. A., Tatlı A. M., ALAN Ö., Keskin G. Y., KARADURMUŞ N., KARAKAYA S., et al.
Clinical Lung Cancer , cilt.26, sa.8, 2025 (SCI-Expanded, Scopus)

5. Treatment outcomes and prognostic factors in patients with driver mutant non-small cell lung cancer and de novo brain metastases

Kahraman S., KARAKAYA S., Kaplan M. A., SEZGİN GÖKSU S., Ozturk A., Isleyen Z. S., et al.
Scientific Reports , cilt.14, sa.1, 2024 (SCI-Expanded, Scopus)

6. Clinicopathological features of non-carcinoid malignant epithelial appendix tumors and risk factors for recurrence, single-center experience

ATEŞ Ö., AKSEL B., KARADAĞ İ., KARAKAYA S., Sunar V., Oksuzoglu O. B.
Indian Journal of Cancer , cilt.61, sa.2, ss.305-311, 2024 (SCI-Expanded, Scopus)

7. Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy

Karacin C., Oksuzoglu B., Demirci A., Keskinkılıç M., Baytemür N. K., Yılmaz F., et al.
BMC Cancer , cilt.23, sa.1, 2023 (SCI-Expanded, Scopus)

8. Clinical Features and Prognostic Factors of Metastatic Non-Clear Cell Renal Cell Carcinoma: A Multicenter Study from the Turkish Oncology Group Kidney Cancer Consortium

Erol C., YEKEDÜZ E., Tural D., KARAKAYA S., Şentürk Öztaş N., Uçar G., et al.
Urologia Internationalis , cilt.107, sa.6, ss.595-601, 2023 (SCI-Expanded, Scopus)

9. External Validation of a Novel Risk Model in Patients With Favorable Risk Renal Cell Carcinoma Defined by International Metastatic Renal Cell Carcinoma Database Consortium (IMDC): Results From the Turkish Oncology Group Kidney Cancer Consortium (TKCC) Database

YEKEDÜZ E., KARAKAYA S., ERTÜRK İ., Tural D., Uçar G., Şentürk Öztaş N., et al.
Clinical Genitourinary Cancer , cilt.21, sa.1, ss.175-182, 2023 (SCI-Expanded, Scopus)

10. The Potential Prognostic Marker TyG Index Predicts Time to Brain Metastasis at HER2 Positive Breast Cancer

KARADAĞ İ., KARAKAYA S., AKKAN T., Demir B., Alkurt E. G., DOĞAN M.
Cancer Management and Research , cilt.15, ss.311-317, 2023 (SCI-Expanded, Scopus)

11. Crizotinib efficacy and safety in patients with advanced NSCLC harboring MET alterations: A real-life data of Turkish Oncology Group

Gürbüz M., Kiliçkap S., BİLİCİ A., KARADURMUŞ N., Sezer A., ŞENDUR M. A. N., et al.
Medicine (United States) , cilt.101, sa.50, 2022 (SCI-Expanded, Scopus)

12. The relationship between systemic immune inflammation index and survival in patients with metastatic renal cell carcinomatreated withtyrosine kinase inhibitors

Yücel K. B., YEKEDÜZ E., KARAKAYA S., Tural D., ERTÜRK İ., Erol C., et al.
Scientific Reports , cilt.12, sa.1, 2022 (SCI-Expanded, Scopus) Creative Commons License

13. The relationship between pan-immune-inflammation value and survival outcomes in patients with metastatic renal cell carcinoma treated with nivolumab in the second line and beyond: a Turkish oncology group kidney cancer consortium (TKCC) study

YEKEDÜZ E., Tural D., ERTÜRK İ., KARAKAYA S., Erol C., Ercelep Ö., et al.
Journal of Cancer Research and Clinical Oncology , cilt.148, sa.12, ss.3537-3546, 2022 (SCI-Expanded, Scopus) Creative Commons License

14. Clinicopathological Factors in Relation to HER2 Status in Metastatic Gastric Cancer: A Retrospective Observational Study

Gurbuz M., Dogan I., Akkus E., KARADAĞ İ., KARAKAYA S., Erol C., et al.
Journal of Oncological Science , cilt.8, sa.1, ss.14-19, 2022 (Scopus, TRDizin)

15. Non-Invasive Liver Fibrosis Scores can Predict Hepatic Metastasis in Colorectal Cancers

KARAKAYA S., KARADAĞ İ., ATEŞ Ö.
UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi , cilt.32, sa.2, ss.102-108, 2022 (SCI-Expanded, Scopus, TRDizin)

16. The potential prognostic novel markers PIV and PILE score to predict survival outcomes at hepatocellular cancer

KARADAĞ İ., KARAKAYA S., YILMAZ M., ÇAKMAK ÖKSÜZOĞLU Ö. B.
European Review for Medical and Pharmacological Sciences , cilt.26, sa.20, ss.7679-7686, 2022 (SCI-Expanded, Scopus)

17. CA-125/CEA RATIO AS A PROGNOSTIC FACTOR IN TYPE II ENDOMETRIAL CANCER: A SINGLE INSTITUTE EXPERIENCE

KARADAĞ İ., KARAKAYA S., Ateş O., Çakmak Öksüzoğlu O. B.
World Cancer Research Journal , cilt.9, 2022 (Scopus)

18. Nivolumab in metastatic renal cell carcinoma: results from the Turkish Oncology Group Kidney Cancer Consortium database

YEKEDÜZ E., ERTÜRK İ., Tural D., KARADURMUŞ N., KARAKAYA S., Hlzal M., et al.
Future Oncology , cilt.17, sa.35, ss.4861-4869, 2021 (SCI-Expanded, Scopus)

19. Evaluation of factors predicting pathologic complete response in locally advanced HER2 positive breast cancer treated with neoadjuvant pertuzumab, trastuzumab and chemotherapy; Real life data

ATEŞ Ö., Oksuzoglu O. B., AKTAŞ B. Y., KARADAĞ İ., Esen S., KARAKAYA S., et al.
Journal of B.U.ON. , cilt.26, sa.4, ss.1398-1404, 2021 (SCI-Expanded, Scopus)

20. Association of serum proprotein convertase Subtilisin/Kexin Type 9 (PCSK9) level with thyroid function disorders

YILDIRIM A., OR KOCA A., BEYAN E., DOĞAN Ö., KARAKAYA S., Aksoz Z., et al.
European Review for Medical and Pharmacological Sciences , cilt.25, sa.17, ss.5511-5517, 2021 (SCI-Expanded, Scopus)

21. Neutrophil–lymphocyte ratio as a prognostic factor for survival in patients with advanced renal cell carcinoma (Turkish Oncology Group Study)

Hizal M., Sendur M. A., YAŞAR H. A., Bir Yucel K., Arslan C., Ucar G., et al.
Journal of Oncology Pharmacy Practice , cilt.26, sa.7, ss.1583-1589, 2020 (SCI-Expanded, Scopus)

22. The relationship between prognostic nutritional index and treatment response in patients with metastatic renal cell cancer

YAŞAR H. A., Bir Yucel K., Arslan C., Ucar G., KARAKAYA S., Bilgin B., et al.
Journal of Oncology Pharmacy Practice , cilt.26, sa.5, ss.1110-1116, 2020 (SCI-Expanded, Scopus)

23. Trimester-specific reference intervals of thyroid function tests in Turkish pregnants

Bulur O., Atak Z., Ertugrul D. T., BEYAN E., Gunakan E., KARAKAYA S., et al.
Gynecological Endocrinology , cilt.36, sa.5, ss.413-416, 2020 (SCI-Expanded, Scopus)

24. CAN NEUTROPHIL/LYMPHOCYTE RATIO BE USED AS AN INDICATOR OF INFLAMMATION IN PATIENTS WITH HYPERTHYROIDISM? DA LI SE ODNOS NEUTROFILA/LIMFOCITA MO@E KORISTITI KAO INDIKATOR UPALE KOD PACIJENATA SA HIPERTIREOIDIZMOM?

Dağdeviren M., AKKAN T., Yapar D., KARAKAYA S., Dağdeviren T., Ertuğrul D., et al.
Journal of Medical Biochemistry , cilt.39, sa.1, ss.7-12, 2020 (SCI-Expanded, Scopus) Creative Commons License

25. The neutrophil-lymphocyte ratio and its relationship with insulin resistance in obes

KARAKAYA S., ALTAY M., Kaplan Efe F., KARADAĞ İ., Ünsal O., Bulur O., et al.
Turkish Journal of Medical Sciences , cilt.49, sa.1, ss.245-248, 2019 (SCI-Expanded, Scopus, TRDizin)

26. Renal function improves with the treatment of hypothyroidism

Bulur O., Dal K., Ertugrul D. T., Eser M., Kaplan Efe F., KARAKAYA S., et al.
Endocrine Research , cilt.42, sa.3, ss.246-251, 2017 (SCI-Expanded, Scopus)

27. The role of insulin - Like growth factor - 1 on steatohepatitis

Dal K., Bulur O., ATA N., Yeniova A. O., Baser S., KARAKAYA S., et al.
Acta Gastro-Enterologica Belgica , cilt.80, sa.1, ss.21-24, 2017 (SCI-Expanded, Scopus)

28. The effect of glycemic control on CEA, CA 19-9, amylase and lipase levels

ATA N., Dal K., Kucukazman M., Yeniova A. Ö., KARAKAYA S., Unsal O., et al.
Open Medicine (Poland) , cilt.10, sa.1, ss.8-13, 2015 (SCI-Expanded, Scopus)
Metrikler

Yayın

28

Yayın (WoS)

26

Yayın (Scopus)

28

H-İndeks (WoS)

11

Atıf (Scopus)

270

H-İndeks (Scopus)

11

Atıf (TrDizin)

7

H-İndeks (TrDizin)

2

Atıf (Diğer Toplam)

7

Proje

1

Tez Danışmanlığı

4

Açık Erişim

7